Hematological Malignancies
Conditions
Interventions
Observation Group for Treatment of Hematological Malignant Tumors:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with hematological malignancies through histopathological or cytological examination; 2. Undergoing chemotherapy with a regimen containing high-dose methotrexate (single dose >= 1 g/m^2); 3. Age >= 18 years old; 4. Completed 24-hour, 48-hour and 72-hour methotrexate blood concentration tests; 5. Able to obtain detailed information on methotrexate treatment, including dosage, infusion time, blood concentration, hydration and alkalization status, and folic acid calcium rescue plan.
Exclusion criteria
Exclusion criteria: 1. Patients who have interrupted methotrexate chemotherapy; 2. Patients with severe renal dysfunction (eGFR < 30 mL/min/1.73m^2) before methotrexate administration or those requiring renal replacement therapy, as well as patients with other severe organ dysfunction such as severe liver failure (Child-Pugh C grade) or severe cardiac dysfunction (NYHA IV grade); 3. Patients with other blood diseases; 4. Patients with severely incomplete clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delayed clearance of methotrexate; | — |
Countries
China
Contacts
Public ContactMengfei Dai
Zhejiang Provincial Cancer Hospital
Outcome results
None listed